The Ledger
Every statement that passed quotation and attribution checks. Mix any filter with any other: certainty 1/5, debate potential 5/5, or both at once.
why aren't all 16 resolved? a statement only gets an assessment when the public record can support or contradict it. opinions and what-ifs never can, and 0 checkable ones are still open, waiting for their date. predictions held up or didn't; assertions are supported or contradicted. on every card: ▮▮▮▮▮ certainty · ▮▮▮▮▮ debate potential. speakers are clickable
Solomon: Immune system mapping enables data-driven drug discovery
“Having a map of the human immune system will enable researchers to apply data mining tools to come up with novel ways to develop and discover therapeutics.”
Solomon predicts immune profiling will enable preventative healthcare within 15 years
“The vision that I have and the hope that I have is that maybe in 15 years, We'll be able to use our new profile and capabilities to help people remain healthy.”
Solomon: Bridging animal testing to humans is biotech's biggest challenge
“Understanding how to bridge the gap between the human immune response and the way that drugs are being tested in animal models. Is, I believe, the biggest challenge that the biopharma and biotechnology industry should face and will face in the coming, ah, deca…”
Solomon: Immunai's database spans over 100,000 patients across 500 diseases
“It is the largest of its kind database of the immune system with a single cell resolution. So today we have a database that spans over 100,000 patients, over 500 different disease indications, thousands of studies, and we're trying to put as much clinical cont…”
Solomon: Immunai's platform successfully identifies superior clinical drug combinations
“We were able to show quite definitively that our platform can identify the preferred combination arm that will demonstrate a superior immune response. So it happened already.”
Solomon founded Immunai knowing nothing about biology, medicine, or business
“I started the company. I didn't know anything about biology, medicine, business development, and I had to ask a lot of questions”
Solomon: Humans lack the intuition to analyze high-dimensional biological data
“No human being will have the intuition to analyze all the relevant data. You have to use a machine to analyze the data.”
Solomon: Unlike autonomous vehicles, biotech AI must vastly outperform human experts
“For autonomous vehicles, you have experts, and every driver that can drive a car, you can ask whether an autonomous vehicle drives as good as a driver, like me and you. For drug development, even the best scientists in the world, they don't know, as we mention…”
Solomon: Acknowledging High Risk Drives Non-Conformist Problem Solving
“When you understand that the risk is high, you are more likely to take steps that are going to be non-conformist and non-conformal, and you're going to think about the problem in a different way.”
Solomon: Immunai generates one terabyte of data per patient sample
“We are going to generate one terabyte of information from every sample that we take from a patient.”
Solomon: Dramatic compute growth over five years enables immune system mapping
“What happened in the past five years was in some sense a perfect storm where compute power has grown dramatically. We have seen more and more, and we keep seeing more and more technologies in biology and chemistry that allow us to measure things in, you know, …”
Solomon: Immune system mapping will enable treatments for rare diseases
“When we understand the immune system better and better, and we map more areas of the immune system, we will be able to cope with more rare autoimmune indications, orphan disease, and other you know, cancer indications that only few patients have.”
Solomon: Immunotherapy development costs $2.6B+ with a 90%+ failure rate
“So to develop a new immunotherapy takes more than 2.6 billion dollars. It takes more than 10 years of research and development before market. And more than 90% of drugs fail To get an FDA approval.”
Solomon: Immunai generates commercial revenue from large biopharma partnerships
“First is that we are already working and making money by working with our partnerships you know, large Biopharmaceutical companies are paying us good money to help them further develop and improve the development of their drug candidates and other drugs.”
Solomon: Immune Profiling Pinpoints Gene Differences Explaining Cancer Immunotherapy Non-Response
“And the interesting thing is that when we do our immune profiling of patients pre and post therapies, we see that some very subtle nuanced differences between responders and non-responders explain, or at least partially explain the reason. So we can find that …”